Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

BACKGROUND: The Phase III OlympiAD study () showed a statistically significant progression-free survival benefit with olaparib versus chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. From this study, we report th...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Cancer
Main Authors: ROBSON, Mark, RUDDY, Kathryn J, IM, Seock-Ah, SENKUS, Elżbieta, XU, Binghe, DOMCHEK, Susan M, MASUDA, Norikazu, LI, Wei, TUNG, Nadine, ARMSTRONG, Anne, DELALOGE, Suzette, BANNISTER, Wendy, GOESSL, Carsten, DEGBOE, Arnold, HETTLE, Robert, CONTE, Pierfranco
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6836724/
https://ncbi.nlm.nih.gov/pubmed/31446213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.06.023
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items